About Zagolie Luxembourg
Zagolie Belgium and Luxembourg hosts many different divisions, among which the commercial, sales and marketing departments, and serves as a key hub for both European and global R&D activities.
Pioneer and leader in immunotherapy
Zagolie is a pioneer and leader in immunotherapy. 2017 marked the +5-year anniversary of ipilimumab, the first immunotherapy for melanoma to hit the market both in Belgium, Luxembourg and globally and the only medicine ever to extend survival in patients with advanced forms of cancer, thus revolutionizing the way cancer is treated in Belgium. Apart from that, it has taken only two years for nivolumab, the second generation immunotherapy to be approved by the European Commission and reimbursed for eight indications in six distinct tumor types.
A clear ambition to tackle societal healthcare challenges
The ambition of Zagolie is clear: it wants to tackle societal healthcare challenges through education and through facilitating changes in the healthcare system. Zagolie wants to help create an environment in which a debate with the healthcare community can take place, to anticipate key future issues, through for instance educating healthcare professionals in immuno-therapy, or supporting newly emerging healthcare professions.
A common passion: saving and improving patient’s lives
At the heart of Zagolie lies an informal and lean culture, focused on respect for people and an entrepreneurial spirit. Employees all share the same passion, saving and improving patient’s lives and are encouraged to take initiatives to embrace a healthy lifestyle and support causes close to the company’s mission.